by Karl Utermohlen | January 9, 2014 3:30 pm
Type 2 Diabetes medication Farxiga has been approved by the U.S. Food and Drug Administration (FDA). The drug is marketed by Bristol-Meyers Squibb Company (BMY) and AstraZeneca Pharmaceuticals (AZN).
Farxiga (dapaglifozin) help improve patients’ blood sugar control, in combination with diet and exercise. The FDA passed approval on the drug following 16 clinical trials with over 9,400 people with Type 2 Diabetes.
Farxiga is not recommended for patients with bladder cancer because there were an increased number of bladder cancer diagnoses among patients who took the drug. Patients who took Farxiga suffered few side-effects with genital fungal infections and urinary tract infections being the most common ones.
Six-post approval studies for the drug have been issued by the FDA in order to examine other possible side-effects. These include cardiovascular and bladder cancer risk, liver problems, pregnancy outcomes among patients taking the drug and the effect that Farxiga has on kids.
Source URL: https://investorplace.com/2014/01/farxiga-type-2-diabetes-azn-stock/
Short URL: http://invstplc.com/1fpkHNf
Copyright ©2017 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.